p.123 抽出テキスト
cardiomyopathies. Eur J Heart Fail 2011;13:584–594. https://doi.org/10.1093/eurjhf/ hfr040 1138. Castrini AI, Lie OH, Leren IS, Estensen ME, Stokke MK, Klaeboe LG, et al. Number of pregnancies and subsequent phenotype in a cross-sectional cohort of women with arrhythmogenic cardiomyopathy. Eur Heart J Cardiovasc Imaging 2019;20:192–198. https://doi.org/10.1093/ehjci/jey061 1139. Platonov PG, Castrini AI, Svensson A, Christiansen MK, Gilljam T, Bundgaard H, et al. Pregnancies, ventricular arrhythmias, and substrate progression in women with arrhythmogenic right ventricular cardiomyopathy in the Nordic ARVC Registry. Europace 2020;22:1873–1879. https://doi.org/10.1093/europace/euaa136 1140. Gandjbakhch E, Varlet E, Duthoit G, Fressart V, Charron P, Himbert C, et al. Pregnancy and newborn outcomes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Int J Cardiol 2018;258:172–178. https://doi.org/10.1016/j.ijcard.2017. 11.067 1141. Wu L, Liang E, Fan S, Zheng L, Hu F, Liu S, et al. Effect of pregnancy in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2020;125:613–617. https://doi.org/10. 1016/j.amjcard.2019.11.008 1142. Castrini AI, Skjolsvik E, Estensen ME, Almaas VM, Skulstad H, Lyseggen E, et al. Pregnancy and progression of cardiomyopathy in women with LMNA genotypepositive. J Am Heart Assoc 2022;11:e024960. https://doi.org/10.1161/JAHA.121.024960 1143. Grewal J, Siu SC, Ross HJ, Mason J, Balint OH, Sermer M, et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 2009;55:45–52. https://doi.org/ 10.1016/j.jacc.2009.08.036 1144. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010;121:1465–1473. https://doi.org/10. 1161/CIRCULATIONAHA.109.901496 1145. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017;38:2671–2679. https://doi.org/10.1093/eurheartj/ ehx355 1146. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:207–221. https://doi. org/10.1016/j.jacc.2019.11.014 1147. Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019; 21:827–843. https://doi.org/10.1002/ejhf.1493 1148. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, et al. ACC/ AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002;105:1257–1267. https://doi.org/10.1161/circ.105.10.1257 1149. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014;35:2383–2431. https://doi.org/10.1093/ eurheartj/ehu282 1150. Sahoo RK, Dash SK, Raut PS, Badole UR, Upasani CB. Perioperative anesthetic management of patients with hypertrophic cardiomyopathy for noncardiac surgery: a case series. Ann Card Anaesth 2010;13:253–256. https://doi.org/10.4103/0971-9784. 69049 1151. Dhillon A, Khanna A, Randhawa MS, Cywinski J, Saager L, Thamilarasan M, et al. Perioperative outcomes of patients with hypertrophic cardiomyopathy undergoing non-cardiac surgery. Heart 2016;102:1627–1632. https://doi.org/10.1136/heartjnl- 2016-309442 1152. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–731. https://doi.org/10.1002/ejhf.1494 1153. Coats CJ, Gallagher MJ, Foley M, O’Mahony C, Critoph C, Gimeno J, et al. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J 2013;34:2529–2537. https://doi. org/10.1093/eurheartj/eht070 1154. D’Amato R, Tomberli B, Castelli G, Spoladore R, Girolami F, Fornaro A, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with hypertrophic cardiomyopathy. Am J Cardiol 2013;112:1190–1196. https://doi.org/ 10.1016/j.amjcard.2013.06.018 1155. van der Meulen M, den Boer S, du Marchie Sarvaas GJ, Blom N, Ten Harkel ADJ, Breur H, et al. Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome. ESC Heart Fail 2021;8:1472–1481. https://doi.org/10.1002/ehf2.13233 1156. Cheng H, Lu M, Hou C, Chen X, Wang J, Yin G, et al. Relation between N-terminal pro-brain natriuretic peptide and cardiac remodeling and function assessed by cardiovascular magnetic resonance imaging in patients with arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2015;115:341–347. https://doi.org/10.1016/j. amjcard.2014.10.040 1157. Chivulescu M, Lie OH, Popescu BA, Skulstad H, Edvardsen T, Jurcut RO, et al. High penetrance and similar disease progression in probands and in family members with arrhythmogenic cardiomyopathy. Eur Heart J 2020;41:1401–1410. https://doi.org/10. 1093/eurheartj/ehz570 1158. Norrish G, Forshaw N, Woo C, Avanis MC, Field E, Cervi E, et al. Outcomes following general anaesthesia in children with hypertrophic cardiomyopathy. Arch Dis Child 2019;104:471–475. https://doi.org/10.1136/archdischild-2018-315366 1159. Kazmers A, Cerqueira MD, Zierler RE. Perioperative and late outcome in patients with left ventricular ejection fraction of 35% or less who require major vascular surgery. J Vasc Surg 1988;8:307–315. https://doi.org/10.1016/0741-5214(88)90283-2 1160. Healy KO, Waksmonski CA, Altman RK, Stetson PD, Reyentovich A, Maurer MS. Perioperative outcome and long-term mortality for heart failure patients undergoing intermediate- and high-risk noncardiac surgery: impact of left ventricular ejection fraction. Congest Heart Fail 2010;16:45–49. https://doi.org/10.1111/j.1751-7133. 2009.00130.x 1161. Barbara DW, Hyder JA, Behrend TL, Abel MD, Schaff HV, Mauermann WJ. Safety of noncardiac surgery in patients with hypertrophic obstructive cardiomyopathy at a tertiary care center. J Cardiothorac Vasc Anesth 2016;30:659–664. https://doi.org/10. 1053/j.jvca.2015.08.017 1162. Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62:1365–1372. https://doi.org/10.1016/j.jacc.2013.05.069 1163. Ledwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013;310:66–74. https://doi.org/10.1001/jama.2013.7588 1164. Rodseth RN, Biccard BM, Le Manach Y, Sessler DI, Lurati Buse GA, Thabane L, et al. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol 2014;63:170–180. https://doi.org/10.1016/j.jacc. 2013.08.1630 1165. Karthikeyan G, Moncur RA, Levine O, Heels-Ansdell D, Chan MT, Alonso-Coello P, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol 2009;54:1599–1606. https://doi.org/10.1016/j. jacc.2009.06.028 1166. Ahmad F, McNally EM, Ackerman MJ, Baty LC, Day SM, Kullo IJ, et al. Establishment of specialized clinical cardiovascular genetics programs: recognizing the need and meeting standards: a scientific statement from the American Heart Association. Circ Genom Precis Med 2019;12:e000054. https://doi.org/10.1161/HCG.000000000000 0054 1167. Burton H, Alberg C, Stewart A. Heart to Heart: Inherited Cardiovascular Conditions Services. Cambridge, UK: PHG Foundation, 2009. 1168. Chamberlain AM, Agarwal SK, Folsom AR, Duval S, Soliman EZ, Ambrose M, et al. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm 2011;8:1160–1166. https://doi.org/10. 1016/j.hrthm.2011.03.038 1169. Kamimura D, Cain LR, Mentz RJ, White WB, Blaha MJ, DeFilippis AP, et al. Cigarette smoking and incident heart failure: insights from the Jackson Heart Study. Circulation 2018;137:2572–2582. https://doi.org/10.1161/CIRCULATIONAHA.117.031912 1170. Gottdiener JS, Buzkova P, Kahn PA, DeFilippi C, Shah S, Barasch E, et al. Relation of cigarette smoking and heart failure in adults >/=65 years of age (from the Cardiovascular Health Study). Am J Cardiol 2022;168:90–98. https://doi.org/10. 1016/j.amjcard.2021.12.021 1171. Park J, Lee H-J, Kim SK, Yi J-E, Shin DG, Lee JM, et al. Smoking aggravates ventricular arrhythmic events in non-ischemic dilated cardiomyopathy associated with a late gadolinium enhancement in cardiac MRI. Sci Rep 2018;8:15609. https://doi.org/10. 1038/s41598-018-34145-9 1172. Smith D, Toff W, Joy M, Dowdall N, Johnston R, Clark L, et al. Fitness to fly for passengers with cardiovascular disease. Heart 2010;96(Suppl 2):ii1–ii16. https://doi.org/ 10.1136/hrt.2010.203091 1173. Fumagalli C, Olivotto I. The importance of sex differences in patients with hypertrophic cardiomyopathy – tailoring management and future perspectives. Am J Med Sci 2020;360:433–434. https://doi.org/10.1016/j.amjms.2020.07.004 1174. Terauchi Y, Kubo T, Baba Y, Hirota T, Tanioka K, Yamasaki N, et al. Gender differences in the clinical features of hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Cardiol 2015;65:423–428. https://doi. org/10.1016/j.jjcc.2014.07.010 ESC Guidelines 3625 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026